1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Valeo Pharma Inc.
  6. Financials
    VPH   CA91915B1085

VALEO PHARMA INC.

(VPH)
  Report
Delayed CANADIAN NATIONAL STOCK EXCHANGE  -  03/28 03:57:37 pm EDT
0.6600 CAD    0.00%
05/09Valeo Pharma Inc. Opens the Market
AQ
04/28Valeo pharma announces results of annual meeting of shareholders, appointments and options and rsu grants
AQ
04/28Valeo Pharma Inc. Appoints Marc Léger as Director
CI
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: October 2019 2020 2021 2022 2023 2024
Capitalization1 15,049,364,642,5--
Enterprise Value (EV)1 15,049,364,642,542,542,5
P/E ratio -3,79x---3,06x26,0x4,73x
Yield ------
Capitalization / Revenue 2,28x6,60x4,77x1,18x0,57x0,38x
EV / Revenue 2,28x6,60x4,77x1,18x0,57x0,38x
EV / EBITDA --19,0x-5,31x-5,65x3,87x1,37x
Price to Book ----5,78x-10,4x4,00x
Nbr of stocks (in thousands) 56 65964 00478 80081 649--
Reference price (CAD) 0,270,770,820,520,520,52
Announcement Date 02/27/202002/24/202102/28/2022---
1 CAD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: October 2019 2020 2021 2022 2023 2024
Net sales1 6,587,4713,636,074,1112
EBITDA1 --2,60-12,2-7,5111,030,9
Operating profit (EBIT)1 --4,34-12,9-7,7411,037,0
Operating Margin --58,1%-95,4%-21,5%14,8%33,0%
Pre-Tax Profit (EBT)1 ----13,44,0320,1
Net income1 ----13,42,9614,7
Net margin ----37,3%3,99%13,1%
EPS2 -0,07---0,170,020,11
Dividend per Share ------
Announcement Date 02/27/202002/24/202102/28/2022---
1 CAD in Million
2 CAD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: October 2021 Q3 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 5,674,246,4911,913,8
EBITDA1 -2,26-4,40-3,39-0,850,08
Operating profit (EBIT)1 -2,62-4,90-3,86-1,740,01
Operating Margin -46,2%-115%-59,5%-14,6%0,09%
Pre-Tax Profit (EBT)1 -2,97-5,86-4,57-1,56-1,44
Net income1 -2,97-5,86-4,57-1,56-1,44
Net margin -52,4%-138%-70,4%-13,1%-10,4%
EPS2 -0,04-0,07-0,06-0,02-0,02
Dividend per Share -----
Announcement Date 09/22/202103/24/2022---
1 CAD in Million
2 CAD
Estimates
Balance Sheet Analysis
Fiscal Period: October 2019 2020 2021 2022 2023 2024
Net Debt ------
Net Cash position ------
Leverage (Debt / EBITDA) ------
Free Cash Flow1 --5,36-13,2-10,86,1621,9
ROE (Net Profit / Equities) ----163%137%
Shareholders' equity1 ----1,8110,8
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 ----0,09-0,050,13
Cash Flow per Share2 ----0,240,010,14
Capex1 -0,060,900,170,100,10
Capex / Sales -0,83%6,65%0,47%0,13%0,09%
Announcement Date 02/27/202002/24/202102/28/2022---
1 CAD in Million
2 CAD
Estimates
Key data
Capitalization (CAD) 42 457 530
Capitalization (USD) 33 033 938
Net sales (CAD) 13 557 000
Net sales (USD) 10 547 978
Number of employees 100
Sales / Employee (CAD) 135 570
Sales / Employee (USD) 105 480
Free-Float 53,2%
Free-Float capitalization (CAD) 22 594 513
Free-Float capitalization (USD) 17 579 585
EPS & Dividend